Overview

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Status:
Suspended

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

Open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Trials Ireland

Treatments:

Denosumab